Citius Pharmaceuticals Inc (CTXR) Stock Price Peaks at $0.7800 During Trading

The closing price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) was $0.73 for the day, down -4.53% from the previous closing price of $0.77. In other words, the price has decreased by -$0.0347 from its previous closing price. On the day, 577924 shares were traded. CTXR stock price reached its highest trading level at $0.7800 during the session, while it also had its lowest trading level at $0.7304.

Ratios:

Our analysis of CTXR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on November 30, 2021, initiated with a Buy rating and assigned the stock a target price of $4.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 117.41M and an Enterprise Value of 97.49M.

Stock Price History:

Over the past 52 weeks, CTXR has reached a high of $1.71, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is 0.7280, while the 200-Day Moving Average is calculated to be 0.8814.

Shares Statistics:

CTXR traded an average of 639.77K shares per day over the past three months and 455.23k shares per day over the past ten days. A total of 158.86M shares are outstanding, with a floating share count of 146.78M. Insiders hold about 7.74% of the company’s shares, while institutions hold 16.96% stake in the company. Shares short for CTXR as of Feb 15, 2024 were 11.58M with a Short Ratio of 18.10, compared to 13.94M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.28% and a Short% of Float of 7.89%.

Earnings Estimates

The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.06, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.

Analysts are recommending an EPS of between -$0.21 and -$0.21 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is $0.12, with 2 analysts recommending between $0.16 and $0.09.

Revenue Estimates

Based on 2 analysts’ estimates, the company’s revenue will be $83.59M in the next fiscal year. The high estimate is $121.3M and the low estimate is $45.89M. The average revenue growth estimate for next year is up 35.40% from the average revenue estimate for this year.

Most Popular

[the_ad id="945"]